2 enrolling by invitation, 2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow KRAS G12C Mutation: new trials by email Literature Review of KRAS G12C Mutation trials Research Report on KRAS G12C Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC fulzerasib - Resectable NSCLC, KRAS G12C Mutation | Phase 2 | Recruiting | Jianxing He | 30 | 2026-01-29 | 2026-03-25 |
| Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance Oncogene-addicted Non Small Cell Lung Cancer, EGFR Mutation | Enrolling by invitation | Chang Gung Memorial Hospital | 40 | 2025-09-01 | 2026-03-17 | |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab Administration of experimental treatment association (sotorasib, panitumumab 5FU) - Colorectal Carcinoma, KRAS G12C Mutation | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 300 | 2025-08-31 | 2025-08-15 |
| The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer IBI351, cetuximab β combined with FOLFIRI - Colorectal Cancer Metastatic, KRAS G12C Mutation | Phase 2 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-22 | 2026-05-11 |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB365, Cetuximab, KQB198 - KRAS G12C Mutation, KRAS G12S Mutation | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 140 | 2025-02-04 | 2026-11-03 |
| Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation BEBT-607Tablets - Advanced or Metastatic Solid Tumor, KRAS G12C Mutation | Phase 1 | Completed | BeBetter Med Inc | 11 | 2023-09-18 | 2026-08-18 |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 50 | 2019-10-17 | 2026-10-30 |
Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (4) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplastic Processes (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Rectal Diseases (2)
Cetuximab (1) · abemaciclib (1) · adagrasib (1) · entrectinib (1) · sintilimab (1) · sotorasib (1)
Alliance for Clinical Trials in Oncology (1) · BeBetter Med Inc (1) · Chang Gung Memorial Hospital (1) · Federation Francophone de Cancerologie Digestive (1) · Jianxing He (1) · Kumquat Biosciences Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (3) · United States (2) · France (1) · Germany (1) · Italy (1) · Spain (1) · Taiwan (1)
Heli Liu, Ph.D (1) · Priscilla Brastianos, MD (1)
U10CA180821 (1)